02043nam a2200433 i 4500001001300000003000600013005001700019007001400036008004100050040003000091042000800121043001200129074001600141086002100157110007300178245017500251264007200426300002200498336000800520337001600528338001900544490007600563500003100639500002900670500004400699500002500743533010600768776018000874776018101054810005801235050002201293650001401315650004701329650004401376650005101420650005001471650005401521655003401575on1076361661OCoLC20190115085009.0he bmb024bbca181127m20189999dcu     b    f000 0 eng c  aPUCPRbengerdacGPOdMvI  apcc  an-us---  a1008-D (MF)0 aY 1.1/8:115-744/1 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce,10aAdvancing High Quality Treatment for Opioid Use Disorders in Medicare Act :breport (to accompany H.R. 5605) (including cost estimate of the Congressional Budget Office). 1a[Washington, D.C.] :b[U.S. Government Publishing Office],c[2018]-  avolumes ;c24 cm.  btxt  bh2rdamedia  bhe2rdacarrier1 aRept. / 115th Congress, 2d session, House of Representatives ;v115-744  aTitle from Part 1 caption.  a"June 12, 2018"--Part 1.  aShipping list no.: 2018-0199-M (pt. 1).  aCRDP Program record.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2018]-emicrofiches : negative.08iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce.tAdvancing High Quality Treatment for Opioid Use Disorders in Medicare Actw(OCoLC)104335582108iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce.tAdvancing High Quality Treatment for Opioid Use Disorders in Medicare Actw(OCoLC)10433557161 aUnited States.bCongress.bHouse.tReport ;v115-744. 4aKF32b.E55 2018ze 0aMedicaid. 0aSubstance abusexTreatmentzUnited States. 0aOpioid abusexTreatmentzUnited States. 0aOpioid abusexTreatmentzUnited StatesxCosts. 0aHealth services accessibilityzUnited States. 0aMedical carexLaw and legislationzUnited States. 7aLegislative materials.2lcgft